Detection of Hypoxia-Regulated MicroRNAs in Blood as Potential Biomarkers of HIF Stabilizer Molidustat
Author:
Marchand Alexandre1, Roulland Ingrid1, Semence Florian1, Schröder Kaja1, Domergue Valérie2, Audran Michel1
Affiliation:
1. Analysis Department ‒ Agence Francaise de Lutte Contre le Dopage (AFLD), 143 Avenue Roger Salengro, 92290 Chatenay- Malabry, France 2. AnimEx Chatenay-Malabry, Plateforme AnimEx IPSIT, Faculte de Pharmacie, Universite Paris-Sud, 5 rue Jean-Baptiste Clement, 92296 Châtenay-Malabry, France
Abstract
Background:
The recent development of drugs that stabilize HIFalpha, called HIF stabilizers,
offers a new strategy for treating anemia. Although these drugs are still in clinical trials, misuse
for doping has already begun. Identifying the biomarkers of HIF stabilizers would therefore help
in detecting this drug misuse by athletes.
Objective:
Our aim was twofold: to determine whether hypoxamiRs, the microRNAs associated with
the cellular response to hypoxia, are potential biomarkers of HIF stabilizers in blood and whether the
response to treatment with an HIF stabilizer differs from the response to a hypoxic environment.
Method:
Rats were treated for 6 days with either a placebo or 2mg/kg of Molidustat, an HIF stabilizer,
or they were put under hypoxia (10% oxygen) for the same length of time. Plasma samples
were analyzed before, during and 48 hours after the treatments.
Results:
EPO concentration increased significantly in plasma during hypoxia and Molidustat treatment
and showed a negative retro-control 2 days after the end of the treatments. On the contrary, circulating
levels of VEGF were not modified. Among the hypoxamiRs tested, miR-130a and miR-21
were significantly increased during Molidustat treatment and miR-21 was still increased 48 hours after
treatment end.
Conclusion:
Although using these microRNAs as biomarkers seems unlikely due to other possible
factors of regulation, this study provides the first identification of a specific effect of HIF stabilizers
on microRNAs. Further investigations are needed to better understand the possible consequences of
such regulation.
Publisher
Bentham Science Publishers Ltd.
Subject
Orthopedics and Sports Medicine,Emergency Medicine,General Medicine
Reference45 articles.
1. Maxwell PH. Exp Physiol, Hypoxia-inducible factor as a physiological regulator.,, 2005, 90,, 791-797, 2. Mole DR, Schlemminger I, McNeill LA. Bioorg Med Chem Lett, 2-Oxoglutarate analogue inhibitors of HIF prolyl hydroxylase.,, 2003, 13,, 2677-2680, 3. Yan L, Colandrea VJ, Hale JJ. Expert Opin Ther Pat, Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia.,, 2010, 20,, 1219-1245, 4. Forristal CE, Winkler IG, Nowlan B, Barbier V, Walkinshaw G, Levesque JP. Blood, Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation.,, 2013, 121,, 759-769, 5. Maxwell PH, Eckardt KU. Nat Rev Nephrol, HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.,, 2016, 12,, 157-168,
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|